Stay updated on Nivolumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The record describes a completed Phase 2 study of nivolumab alone or with vinblastine for adults aged 61 and older with classical Hodgkin lymphoma and coexisting medical conditions. It includes the study design, eligibility criteria, outcomes, and participating locations.
    Difference
    66%
    Check dated 2026-11-10T06:46:33.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T03:28:02.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH terminology change, saying that “Super Intelligence” will be used in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-27T06:37:30.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-20T06:59:27.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T08:26:15.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with an error view. A minimal header/footer and a Home link along with a revision banner are now shown on the screen.
    Difference
    17%
    Check dated 2026-09-22T06:28:15.000Z thumbnail image

Stay in the know with updates to Nivolumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.